{"pmid":32321609,"title":"Diagnostic Options for Coronavirus Disease 2019 (COVID-19).","text":["Diagnostic Options for Coronavirus Disease 2019 (COVID-19).","Infect Control Hosp Epidemiol","Xiao, Yuanyuan","Peng, Zhong","Tan, Caixia","Meng, Xiujuan","Huang, Xun","Wu, Anhua","Li, Chunhui","32321609"],"journal":"Infect Control Hosp Epidemiol","authors":["Xiao, Yuanyuan","Peng, Zhong","Tan, Caixia","Meng, Xiujuan","Huang, Xun","Wu, Anhua","Li, Chunhui"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321609","week":"202017|Apr 20 - Apr 26","doi":"10.1017/ice.2020.168","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664895932634759168,"score":8.518259,"similar":[{"pmid":32329877,"title":"SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.","text":["SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.","SARS-CoV-2 is responsible for the outbreak of severe respiratory illness (COVID-19) in Wuhan City, China and is now spreading rapidly throughout the world. The prompt outbreak of COVID-19 and its quick spread without any controllable measure defines the severity of the situation. In this crisis, a collective pool of knowledge about the advancement of clinical diagnostic and management for COVID-19 is a prerequisite. Here, we summarize all the available updates on the multidisciplinary approaches for the advancement of diagnosis and proposed therapeutic strategies for COVID-19. Moreover, the review discusses different aspects of the COVID-19, including its epidemiology; incubation period; the general clinical features of patients; the clinical features of intensive care unit (ICU) patients; SARS-CoV-2 infection in the presence of co-morbid diseases and the clinical features of pediatric patients infected with the SARS-CoV-2. Advances in various diagnostic approaches, such as the use of real-time polymerase chain reaction (RT-PCR), chest radiography, and computed tomography (CT) imaging; and other modern diagnostic methods, for this infection have been highlighted. However, due to the unavailability of adequate evidence, presently there are no officially approved drugs or vaccines available against SARS-CoV-2. Additionally, we have discussed various therapeutic strategies for COVID-19 under different categories, like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent advancements and strategies for diagnosis and therapy of COVID-19.","Eur Rev Med Pharmacol Sci","Chakraborty, C","Sharma, A R","Sharma, G","Bhattacharya, M","Lee, S S","32329877"],"abstract":["SARS-CoV-2 is responsible for the outbreak of severe respiratory illness (COVID-19) in Wuhan City, China and is now spreading rapidly throughout the world. The prompt outbreak of COVID-19 and its quick spread without any controllable measure defines the severity of the situation. In this crisis, a collective pool of knowledge about the advancement of clinical diagnostic and management for COVID-19 is a prerequisite. Here, we summarize all the available updates on the multidisciplinary approaches for the advancement of diagnosis and proposed therapeutic strategies for COVID-19. Moreover, the review discusses different aspects of the COVID-19, including its epidemiology; incubation period; the general clinical features of patients; the clinical features of intensive care unit (ICU) patients; SARS-CoV-2 infection in the presence of co-morbid diseases and the clinical features of pediatric patients infected with the SARS-CoV-2. Advances in various diagnostic approaches, such as the use of real-time polymerase chain reaction (RT-PCR), chest radiography, and computed tomography (CT) imaging; and other modern diagnostic methods, for this infection have been highlighted. However, due to the unavailability of adequate evidence, presently there are no officially approved drugs or vaccines available against SARS-CoV-2. Additionally, we have discussed various therapeutic strategies for COVID-19 under different categories, like the possible treatment plans with drug (antiviral drugs and anti-cytokines) therapy for disease prevention. Lastly, potentials candidates for the vaccines against SARS-CoV-2 infection have been described. Collectively, the review provides an overview of the SARS-CoV-2 infection outbreak along with the recent advancements and strategies for diagnosis and therapy of COVID-19."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Chakraborty, C","Sharma, A R","Sharma, G","Bhattacharya, M","Lee, S S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329877","week":"202017|Apr 20 - Apr 26","doi":"10.26355/eurrev_202004_20871","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664996914752389121,"score":54.390453},{"pmid":32196453,"title":"Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19).","text":["Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19).","Curr Med Imaging","Sun, Zhonghua","32196453"],"journal":"Curr Med Imaging","authors":["Sun, Zhonghua"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196453","week":"202012|Mar 16 - Mar 22","doi":"10.2174/1573405616999200320163751","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664640930678833153,"score":49.75648},{"pmid":32251798,"title":"Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","text":["Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.","OBJECTIVE: To investigate the diagnostic value of serological test and dynamitic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: We retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with suspected infection who were finally excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivity of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificity were 100% and 90.9%, respectively. In COVID-19 group, IgM positive rate almost increased first then decreased over time, however, IgG positive rate increased till 100% and was higher than IgM all the time. IgM positive rate and titer were not significantly different before and after viral negative. IgG positive rate was up to 90% and not significantly different before and after viral negative. However, the median titer of IgG after viral negative was twice than that before with significant difference. CONCLUSION: Viral serological test is an effective diagnostic means for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than that of IgM in COVID-19.","Int J Infect Dis","Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang","32251798"],"abstract":["OBJECTIVE: To investigate the diagnostic value of serological test and dynamitic variance of serum antibody in coronavirus disease 2019 (COVID-19). METHODS: We retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with suspected infection who were finally excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis. RESULTS: Compared to molecular detection, the sensitivity of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificity were 100% and 90.9%, respectively. In COVID-19 group, IgM positive rate almost increased first then decreased over time, however, IgG positive rate increased till 100% and was higher than IgM all the time. IgM positive rate and titer were not significantly different before and after viral negative. IgG positive rate was up to 90% and not significantly different before and after viral negative. However, the median titer of IgG after viral negative was twice than that before with significant difference. CONCLUSION: Viral serological test is an effective diagnostic means for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than that of IgM in COVID-19."],"journal":"Int J Infect Dis","authors":["Jin, Yujiao","Wang, Miaochan","Zuo, Zhongbao","Fan, Chaoming","Ye, Fei","Cai, Zhaobin","Wang, Ying","Cui, Huaizhong","Pan, Kenu","Xu, Aifang"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251798","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.065","keywords":["COVID-19","Immunoglobulin G","Immunoglobulin M","SARS-CoV-2","diagnosis","serological test"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663352136223686657,"score":47.807693},{"pmid":32241244,"title":"Diagnostic Value and Key Features of Computed Tomography in Coronavirus Disease 2019.","text":["Diagnostic Value and Key Features of Computed Tomography in Coronavirus Disease 2019.","On 31 December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, China, and caused the outbreak of the Coronavirus Disease 2019 (COVID-19). To date, computed tomography (CT) findings have been recommended as major evidence for the clinical diagnosis of COVID-19 in Hubei, China. This review focuses on the imaging characteristics and changes throughout the disease course in patients with COVID-19 in order to provide some help for clinicians. Typical CT findings included bilateral ground-glass opacity, pulmonary consolidation, and prominent distribution in the posterior and peripheral parts of the lungs. This review also provides a comparison between COVID-19 and other diseases that have similar CT findings. Since most patients with COVID-19 infection share typical imaging features, radiological examinations have an irreplaceable role in screening, diagnosis and monitoring treatment effects in clinical practice.","Emerg Microbes Infect","Li, Bingjie","Li, Xin","Wang, Yaxuan","Han, Yikai","Wang, Yidi","Wang, Chen","Zhang, Guorui","Jin, Jianjun","Jia, Hongxia","Fan, Feifei","Ma, Wang","Liu, Hong","Zhou, Yue","32241244"],"abstract":["On 31 December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, China, and caused the outbreak of the Coronavirus Disease 2019 (COVID-19). To date, computed tomography (CT) findings have been recommended as major evidence for the clinical diagnosis of COVID-19 in Hubei, China. This review focuses on the imaging characteristics and changes throughout the disease course in patients with COVID-19 in order to provide some help for clinicians. Typical CT findings included bilateral ground-glass opacity, pulmonary consolidation, and prominent distribution in the posterior and peripheral parts of the lungs. This review also provides a comparison between COVID-19 and other diseases that have similar CT findings. Since most patients with COVID-19 infection share typical imaging features, radiological examinations have an irreplaceable role in screening, diagnosis and monitoring treatment effects in clinical practice."],"journal":"Emerg Microbes Infect","authors":["Li, Bingjie","Li, Xin","Wang, Yaxuan","Han, Yikai","Wang, Yidi","Wang, Chen","Zhang, Guorui","Jin, Jianjun","Jia, Hongxia","Fan, Feifei","Ma, Wang","Liu, Hong","Zhou, Yue"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241244","week":"202014|Mar 30 - Apr 05","doi":"10.1080/22221751.2020.1750307","keywords":["computed tomography","coronavirus disease 2019","diagnosis","sars-cov-2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Wuhan","Hubei","China","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664638249287548930,"score":47.807693},{"pmid":32150622,"title":"Diagnostic Testing for the Novel Coronavirus.","text":["Diagnostic Testing for the Novel Coronavirus.","JAMA","Sharfstein, Joshua M","Becker, Scott J","Mello, Michelle M","32150622"],"journal":"JAMA","authors":["Sharfstein, Joshua M","Becker, Scott J","Mello, Michelle M"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32150622","week":"202011|Mar 09 - Mar 15","doi":"10.1001/jama.2020.3864","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664640874858938368,"score":44.994514}]}